Orforglipron approval timeline: not approved in Canada yet

Where the Canadian file sits in October 2026

Start with the regulator. Health Canada keeps a public list of new drug submissions under review, and it was last updated on September 24, 2026. It shows one orforglipron entry: orforglipron calcium, filed by Eli Lilly Canada Inc., accepted into review in January 2026, classed as a new active substance. The list gives a month, never a day. It also gives no indication, so you cannot tell from it alone whether Health Canada is weighing obesity, type 2 diabetes or both.

The second public calendar belongs to Canada's Drug Agency (CDA-AMC), which advises public drug plans on whether to pay for a medicine. It runs two orforglipron files. SR0955-000 covers weight management and SR0957-000 covers type 2 diabetes. Both were filed before any Canadian authorisation, which is why each page reads "Pre NOC". You can check the weight management schedule yourself on the CDA-AMC orforglipron project page.

So the honest status of the orforglipron approval timeline is this. The drug is not authorised, the review is live, and the reimbursement work is running in parallel rather than waiting its turn. For the wider picture of what that means for patients right now, our guide to Foundayo in Canada today covers it. This page sticks to dates and clocks.

How Health Canada review timing works

Here is the part most articles skip. Health Canada publishes performance standards for every type of drug submission, and they explain most of the orforglipron approval timeline on their own. The full table lives in the Health Canada performance standards guidance. These are the numbers that apply to a brand-new drug like orforglipron.

Screening: the 45-day gate

Screening is a completeness check, not a judgement on the science. If something is missing, Health Canada can issue a screening deficiency notice and the sponsor has to answer before review begins. A file that clears screening is accepted into review, which is the moment the submissions list records. For orforglipron that was January 2026.

Review: 300 days, with the clock paused

The 300-day target runs from acceptance to a first decision, and Health Canada says plainly that it does not count review clock pauses. When reviewers send a question and wait for Lilly's reply, those days fall outside the target. That is why a "300-day" review can stretch past ten months on the calendar. The regulator even credits back a quarter of the fee when it misses its own standard, which tells you the targets are taken seriously.

Now the arithmetic. Count 300 days from a January 2026 acceptance and you land between late October and late November 2026. Our take: that window is the earliest realistic slot for a decision, not a date anyone has promised. Any pause pushes it later.

What a notice of non-compliance would do

If the first review ends with a notice of non-compliance, the sponsor answers and a second review starts, with its own 150-day target. That is the slow path. We have seen nothing public suggesting it applies here, and a sponsor never has to say so. We mention it because it is the single biggest way a Canadian decision slides by months.

Is orforglipron on a fast track in Canada?

People ask this because the US review was so quick. The FDA cleared Foundayo in 71 days using a national priority voucher. That voucher is a US programme. It has no bearing on Health Canada's clock.

Priority review

Health Canada grants priority review to submissions for serious, life-threatening or severely debilitating conditions where nothing with the same profile is on the Canadian market, or where the new drug offers a clear improvement in its benefit-to-risk balance. The target drops from 300 days to 180. Obesity is a serious chronic disease, but Canada already has authorised GLP-1 medicines for it, including Wegovy and Zepbound. The orforglipron entry on the submissions list shows no priority flag. We would not assume it has one.

Project Orbis

Project Orbis is a shared review programme that Health Canada has belonged to since 2019, with partners including Australia, the United Kingdom, Switzerland and Singapore. Health Canada's own page limits it to cancer products, either new active substances or new indications. Orforglipron is not a cancer drug, so Orbis does not apply.

Aligned review: the one special status it does have

The submissions list marks orforglipron as part of an aligned review with a health technology assessment body. Under that process, and with the sponsor's consent, Health Canada and CDA-AMC share information about a file filed before authorisation. It does not speed up the safety review. What it does is shrink the gap between authorisation and a reimbursement recommendation, which is the next hurdle.

What Canada's Drug Agency does, and why its calendar is the best clue

CDA-AMC does not decide whether a drug is safe. It decides whether public plans should pay for it, and on what terms. For a drug that is not a cancer medicine, the recommendation comes from the Canadian Drug Expert Committee. The agency's published procedures set out the steps in order.

• Call for patient and clinician input, open for a set window.
• Review starts, and CDA-AMC builds its clinical and economic reports.
• Draft reports go to the sponsor for comment.
• The expert committee meets and deliberates.
• A draft recommendation goes to the sponsor and drug plans, eight business days after the meeting.
• The draft is posted, and groups get 10 business days to comment.
• A final recommendation follows, then price talks and provincial listing.

Two rules in those procedures matter for timing. First, a sponsor can file on a pre-NOC basis no more than 180 calendar days before it expects its Notice of Compliance. Second, CDA-AMC will not release a draft recommendation until Health Canada has authorised the drug and the agency holds the final product monograph. If the authorisation is late, the file gets bumped to a later committee meeting.

Put those together and the CDA-AMC calendar starts to sketch the orforglipron approval timeline for you. The weight management file was open for input by April 27, 2026. Under the 180-day rule, that implies Lilly expected a Canadian authorisation by around late October 2026 when it filed. The draft recommendation is pencilled in for November 9 to 12, 2026. Our reading: the whole schedule is built around a Canadian decision in roughly October or November. That is an inference from public calendars, not a statement by Lilly or Health Canada.

The type 2 diabetes file trails by about seven weeks. Its committee meeting is set for December 16, 2026, with feedback closing on January 29, 2027. The two reimbursement files run on separate tracks, so one recommendation can land weeks or months before the other, even though Health Canada is weighing a single submission.

How long comparable GLP-1 drugs took to reach Canada

History is the best guide we have for any orforglipron approval timeline. Two recent obesity drugs went through the same system, and their dates are public.

Two lessons jump out. Wegovy cleared Health Canada fast, about 350 days after it was filed in December 2020, then sat unavailable for more than two years while supply caught up. Zepbound took far longer to win authorisation, but Lilly had boxes in pharmacies within two months. Same regulator, opposite bottlenecks.

For orforglipron, we think the Zepbound pattern is the closer match. It is a Lilly product, and a tablet made by chemical synthesis should be easier to scale than an injectable pen. That is our opinion. Lilly has said nothing about Canadian supply plans, and demand surprises have wrecked tidy forecasts before.

Orforglipron approval timeline scenarios: our take

Everything in this section is opinion about the orforglipron approval timeline, built from the public calendars and the history above. We will update it when a real date lands.

Our take: the on-schedule case is the most likely, but we would not bet on a pharmacy shelf before early 2027. Watch two signals. If CDA-AMC posts a draft recommendation for SR0955-000 in mid-November, that is strong evidence Health Canada has issued its Notice of Compliance, since the agency cannot release one before it. If that date moves on the CDA-AMC page, the authorisation has probably slipped too.

Even a quick authorisation does not settle cost. Public coverage depends on the pan-Canadian Pharmaceutical Alliance and each province, and obesity drugs have struggled there. Our orforglipron cost breakdown covers what Foundayo charges in the US and how a Canadian price gets set.

Which countries have approved orforglipron so far

We only list approvals we can trace to a regulator or an official announcement. As of October 5, 2026, that gives us three.

• United States, April 1, 2026. The FDA approved Foundayo for chronic weight management in adults with obesity, or overweight with a weight-related condition.
• United Arab Emirates, April 2026. The Emirates Drug Establishment announced it had registered Foundayo, calling the UAE the second country to do so.
• United Kingdom, August 10, 2026. The MHRA authorised it for weight management and for type 2 diabetes, the first approval in Europe.

The UK case is a useful warning. The MHRA announcement says the drug is not yet available on the NHS, and that NHS use waits on a NICE evaluation. Authorisation and access are separate events in Britain too. Reports of reviews in the European Union and Japan circulate, but we have not found a regulator source we can cite, so we leave them off this list.

What has to happen before a Canadian can fill this prescription

A US approval headline makes it sound like Canada is a few weeks behind. It rarely is. The gap is usually counted in quarters, and three separate things have to happen in order.

1. A Notice of Compliance from Health Canada

This is the authorisation itself. Without it, orforglipron is not a Canadian medicine in any legal sense. Nobody can import it for sale, stock it, advertise it or prescribe it here. Health Canada has one orforglipron submission under review, and Canada's Drug Agency labels both of its files Pre-NOC for that reason.

2. A reimbursement recommendation

CDA-AMC then tells public plans whether to pay and on what terms. A negative or tightly restricted recommendation does not stop sales. It does decide who can afford the drug through a public plan.

3. Price talks, provincial listing and stocking

Each province makes its own coverage call, and wholesalers stock the product. This step catches people out. On recent GLP-1 launches, the gap between authorisation and boxes on a pharmacy shelf has run from weeks to years. A Canadian price does not exist until then. If you need a plan in the meantime, our page on legal ways to get Foundayo and its alternatives walks through the options, and our explainer on how orforglipron works covers the drug itself.

Why this page has no countdown

We could bolt a countdown clock onto this page. Plenty of sites do. We won't, because a countdown needs an end date and none exists. The FDA publishes target action dates for its reviews. Health Canada does not publish them for individual files, so anything precise would be guesswork wearing a lab coat.

Instead we date every event on the orforglipron approval timeline that has actually happened, cite where it came from, and stamp the page with the day a person last checked it. If the stamp says this month and nothing new appears on the timeline, that tells you something real: nothing has moved. For the rest of our coverage, start at our Canadian orforglipron tracker.

Orforglipron approval timeline: common questions